Iams Wealth Management LLC Raises Stake in Amgen Inc. (NASDAQ:AMGN)

Iams Wealth Management LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 27.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,222 shares of the medical research company’s stock after buying an additional 685 shares during the period. Iams Wealth Management LLC’s holdings in Amgen were worth $840,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in shares of Amgen during the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen during the 3rd quarter worth approximately $29,000. Matrix Trust Co purchased a new position in Amgen during the 3rd quarter valued at $36,000. Livelsberger Financial Advisory purchased a new stake in Amgen in the third quarter worth $56,000. Finally, Icon Wealth Advisors LLC increased its stake in Amgen by 3,955.0% in the third quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock worth $56,000 after purchasing an additional 169,748 shares during the period. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

NASDAQ:AMGN opened at $281.28 on Wednesday. The firm has a market cap of $151.20 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company’s 50-day moving average is $271.48 and its two-hundred day moving average is $305.15.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter last year, the business earned $4.96 EPS. Research analysts expect that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.38%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is 115.24%.

Analyst Ratings Changes

A number of brokerages recently weighed in on AMGN. Wolfe Research assumed coverage on shares of Amgen in a report on Friday, November 15th. They set a “peer perform” rating for the company. UBS Group dropped their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. Redburn Partners cut their target price on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Finally, Wells Fargo & Company decreased their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a report on Friday, January 10th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.